AU2013320360B2 - KIR3DL2 binding agents - Google Patents

KIR3DL2 binding agents Download PDF

Info

Publication number
AU2013320360B2
AU2013320360B2 AU2013320360A AU2013320360A AU2013320360B2 AU 2013320360 B2 AU2013320360 B2 AU 2013320360B2 AU 2013320360 A AU2013320360 A AU 2013320360A AU 2013320360 A AU2013320360 A AU 2013320360A AU 2013320360 B2 AU2013320360 B2 AU 2013320360B2
Authority
AU
Australia
Prior art keywords
ser
gly
leu
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013320360A
Other languages
English (en)
Other versions
AU2013320360A1 (en
Inventor
Stephanie Cornen
Laurent Gauthier
Simon Kollnberger
Carine Paturel
Benjamin Rossi
Helene Sicard
Stephanie Zerbib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2013320360A1 publication Critical patent/AU2013320360A1/en
Application granted granted Critical
Publication of AU2013320360B2 publication Critical patent/AU2013320360B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
AU2013320360A 2012-09-19 2013-09-17 KIR3DL2 binding agents Active AU2013320360B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702834P 2012-09-19 2012-09-19
US61/702,834 2012-09-19
PCT/EP2013/069302 WO2014044686A1 (en) 2012-09-19 2013-09-17 Kir3dl2 binding agents

Publications (2)

Publication Number Publication Date
AU2013320360A1 AU2013320360A1 (en) 2015-03-05
AU2013320360B2 true AU2013320360B2 (en) 2018-06-14

Family

ID=49226157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013320360A Active AU2013320360B2 (en) 2012-09-19 2013-09-17 KIR3DL2 binding agents

Country Status (13)

Country Link
US (3) US10577419B2 (cg-RX-API-DMAC7.html)
EP (1) EP2897980B1 (cg-RX-API-DMAC7.html)
JP (1) JP6507097B2 (cg-RX-API-DMAC7.html)
CN (1) CN104640880B (cg-RX-API-DMAC7.html)
AU (1) AU2013320360B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015006060B1 (cg-RX-API-DMAC7.html)
CA (1) CA2881765C (cg-RX-API-DMAC7.html)
DK (1) DK2897980T3 (cg-RX-API-DMAC7.html)
ES (1) ES2770399T3 (cg-RX-API-DMAC7.html)
IL (1) IL237220B (cg-RX-API-DMAC7.html)
MX (1) MX369148B (cg-RX-API-DMAC7.html)
RU (1) RU2682449C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014044686A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181341B2 (en) * 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
BR112015006060B1 (pt) 2012-09-19 2023-03-21 Innate Pharma Anticorpo monoclonal, composição farmacêutica e uso do anticorpo monoclonal
EP3521312B1 (en) 2013-02-20 2021-04-07 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
EP3307784B1 (en) 2015-06-10 2021-12-22 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
EP3313881A1 (en) 2015-06-23 2018-05-02 Innate Pharma Multispecific nk engager proteins
JP6840682B2 (ja) 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
KR20230173745A (ko) * 2016-10-21 2023-12-27 이나뜨 파르마 에스.에이. 항-kir3dl2 작용제에 의한 치료
US20190322767A1 (en) 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins
EP3579879A4 (en) * 2017-02-09 2020-12-16 Memorial Sloan Kettering Cancer Center ANTI-BODY ANTI-KIR3DL1
CA3064443A1 (en) * 2017-05-24 2018-11-29 Development Center For Biotechnology Humanized antibodies against globo h and uses thereof in cancer treatments
CN111093701A (zh) * 2017-06-15 2020-05-01 财团法人生物技术开发中心 含有抗globo h抗体的抗体药物偶联物及其用途
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
CA3079363A1 (en) 2017-11-21 2019-05-31 Innate Pharma Multispecific antigen binding proteins
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
AU2020210710A1 (en) 2019-01-22 2021-07-29 Innate Pharma Treatment of T cell lymphoma
CN110950960B (zh) * 2019-11-26 2021-05-14 中国农业大学 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法
WO2021194942A1 (en) * 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
CN117242093A (zh) 2021-04-05 2023-12-15 先天制药公司 免疫组织化学方法和kir3dl2特异性试剂
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CA3218793A1 (en) 2021-06-09 2022-12-15 Laurent Gauthier Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
IL308531A (en) 2021-06-09 2024-01-01 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
AU2022319782A1 (en) * 2021-07-30 2024-02-15 R.P. Scherer Technologies, Llc Antibodies and antibody conjugates specific for nectin-4 and methods of use thereof
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR20250067128A (ko) 2022-09-15 2025-05-14 아비디큐어 아이피 비.브이. Nk 세포의 종양-표적화를 위한 다중특이적 항원 결합 단백질 및 이의 용도
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025245386A1 (en) * 2024-05-23 2025-11-27 La Jolla Institute For Immunology Kir3dl2 as an anti-cancer target

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050122A2 (en) * 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
WO2010081890A1 (en) * 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1639013B1 (en) * 2003-07-02 2012-09-12 Innate Pharma Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2012047294A2 (en) * 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
WO2014044681A1 (en) * 2012-09-19 2014-03-27 Innate Pharma Kir3dl2 binding agents
BR112015006060B1 (pt) 2012-09-19 2023-03-21 Innate Pharma Anticorpo monoclonal, composição farmacêutica e uso do anticorpo monoclonal
EP3521312B1 (en) 2013-02-20 2021-04-07 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
JP6865582B2 (ja) * 2013-05-29 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｋｉｒ３ｄｌ２は皮膚及び非皮膚末梢ｔ細胞リンパ腫のサブセットをそれぞれ予防及び治療するために有用なバイオマーカー及び治療標的である
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
KR20230173745A (ko) 2016-10-21 2023-12-27 이나뜨 파르마 에스.에이. 항-kir3dl2 작용제에 의한 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050122A2 (en) * 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
WO2010081890A1 (en) * 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRANDO C et al: "Receptors and lytic mediators regulating antitumor activity by the leukemic killer T cell line TALL-104", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 78, no. 2, 1 August 2005 (2005-08-01 ), pages 359-371 *
PENDE et al: THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 2, 1 August 1996 (1996-08-01 ), pages 505-518 *

Also Published As

Publication number Publication date
US10577419B2 (en) 2020-03-03
CA2881765A1 (en) 2014-03-27
IL237220B (en) 2020-02-27
RU2682449C2 (ru) 2019-03-19
MX369148B (es) 2019-10-30
US20240124579A1 (en) 2024-04-18
DK2897980T3 (da) 2020-02-17
JP6507097B2 (ja) 2019-04-24
BR112015006060B1 (pt) 2023-03-21
IL237220A0 (en) 2015-04-30
JP2015535820A (ja) 2015-12-17
WO2014044686A1 (en) 2014-03-27
RU2015104760A (ru) 2016-11-10
US20200199228A1 (en) 2020-06-25
EP2897980A1 (en) 2015-07-29
CN104640880A (zh) 2015-05-20
CN104640880B (zh) 2020-06-09
CA2881765C (en) 2024-02-13
MX2015003476A (es) 2015-08-10
BR112015006060A2 (pt) 2018-09-25
AU2013320360A1 (en) 2015-03-05
US11858990B2 (en) 2024-01-02
US20150232556A1 (en) 2015-08-20
ES2770399T3 (es) 2020-07-01
EP2897980B1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
US20240124579A1 (en) Kir3dl2 binding agents
US20200299380A1 (en) Mica binding agents
KR102586588B1 (ko) 항-cd38 항체를 사용하는 병용 요법
US9828427B2 (en) Anti-KIR3D antibodies
JP2023517252A (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
US11999784B2 (en) Treatment of peripheral T cell lymphoma
KR102345173B1 (ko) 증가된 안정성을 가진 인간화 항체
KR20180118673A (ko) 항-mica 항체
KR20160126027A (ko) 급성 림프아구성 백혈병을 치료하기 위한 항-cd38 항체
EP2958941A1 (en) A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
WO2016030488A1 (en) Treatment of celiac disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)